Business Description
enGene Therapeutics Inc
NAICS : 541710
SIC : 3741
ISIN : CA29286M1059
Total Employee Number:
82Description
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 7.75 | |||||
Equity-to-Asset | 0.83 | |||||
Debt-to-Equity | 0.13 | |||||
Debt-to-EBITDA | -0.27 | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -31.4 | |||||
3-Year EPS without NRI Growth Rate | -33.8 | |||||
3-Year FCF Growth Rate | -37.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 22.44 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 61.71 | |||||
9-Day RSI | 48.18 | |||||
14-Day RSI | 37.84 | |||||
3-1 Month Momentum % | -77.35 | |||||
6-1 Month Momentum % | -80.15 | |||||
12-1 Month Momentum % | -56.84 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 12.57 | |||||
Quick Ratio | 12.57 | |||||
Cash Ratio | 12.03 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -30.9 | |||||
Shareholder Yield % | -112.09 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -56.01 | |||||
ROA % | -46.02 | |||||
ROIC % | -294.73 | |||||
3-Year ROIIC % | -329.79 | |||||
ROC (Joel Greenblatt) % | -1457.36 | |||||
ROCE % | -49.19 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.5 | |||||
Price-to-Tangible-Book | 0.5 | |||||
EV-to-EBIT | 0.78 | |||||
EV-to-EBITDA | 0.79 | |||||
EV-to-Forward-Revenue | 8.04 | |||||
EV-to-FCF | 0.87 | |||||
| Price-to-Net-Current-Asset-Value | 0.59 | |||||
| Price-to-Net-Cash | 0.62 | |||||
Earnings Yield (Greenblatt) % | 128.21 | |||||
FCF Yield % | -87.06 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ENGN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
enGene Therapeutics Inc Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.17 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 103.85 | ||
| 14-Day RSI | 37.84 | ||
| 14-Day ATR ($) | 0.153462 | ||
| 20-Day SMA ($) | 1.712 | ||
| 12-1 Month Momentum % | -56.84 | ||
| 52-Week Range ($) | 1.4 - 12.25 | ||
| Shares Outstanding (Mil) | 66.99 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
enGene Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
enGene Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2026-12-22 | In 168 days | ||
| Fourth quarter earnings results for 2026 | 2026-12-22 | In 168 days | ||
| Third quarter earnings results for 2026 | 2026-09-11 | In 66 days | ||
| Second quarter earnings results for 2026 | 2026-06-15 | 1.62 (-0.61%) | ||
| General meeting for 2026 | 2026-06-09 08:30 | 1.65 (-0.60%) | ||
| Citizens Life Sciences Conference | 2026-03-11 13:40 | 6.94 (-0.57%) | ||
| Barclays 28th Annual Global Healthcare Conference | 2026-03-10 09:00 | 7.05 (-12.53%) | ||
| Guidance call for 2026 | 2026-03-09 08:00 | 8.68 (+1.76%) | ||
| First quarter earnings results for 2026 | 2026-03-09 | 8.68 (+1.76%) | ||
| Oppenheimer 36th Annual Healthcare Life Sciences Conference | 2026-02-26 13:20 | 10.10 (+2.12%) |
Show
Entries
enGene Therapeutics Inc Frequently Asked Questions
What is enGene Therapeutics Inc(ENGN)'s stock price today?
The current price of ENGN is $1.91. The 52 week high of ENGN is $12.25 and 52 week low is $1.40.
When is next earnings date of enGene Therapeutics Inc(ENGN)?
The next earnings date of enGene Therapeutics Inc(ENGN) is 2026-09-11 Est..
Does enGene Therapeutics Inc(ENGN) pay dividends? If so, how much?
enGene Therapeutics Inc(ENGN) does not pay dividend.
Guru Commentaries on NAS:ENGN
No articles.
Press Release
Articles on enGene Therapeutics Inc
No articles.
Headlines
See More- 1
Jun 18, 2026
This Intuit Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday
Benzinga • 7:10am
Jun 16, 2026
W.P. Carey To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday
Benzinga • 7:26am
Jun 15, 2026
enGene Holdings GAAP EPS of $0.43
Seeking Alpha • 9:12am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers